TIDMSCLP
Scancell Holdings Plc
20 May 2019
20 May 2019
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell and Cancer Research UK provide an update on the
development of SCIB2, a novel cancer immunotherapy
SCIB2 to be administered using new nanoparticle formulation in
planned Phase 1/2 clinical trial
Scancell Holdings PLC, a developer of novel immunotherapies for
the treatment of cancer, and Cancer Research UK, the world's
leading cancer charity dedicated to saving lives through research,
are pleased to provide an update on their clinical development
partnership* for the development of Scancell's ImmunoBody(R)
vaccine, SCIB2, as a potential treatment for patients with solid
tumours, including non-small cell lung cancer (NSCLC).
Scancell's ImmunoBody(R) immunotherapy platform activates the
body's immune system by enhancing the uptake and presentation of
cancer antigens to help target and eliminate cancer cells. SCIB2,
Scancell's second ImmunoBody(R) therapy, targets an antigen called
NY-ESO-1, which is expressed on a range of solid tumours, including
NSCLC, oesophageal, ovarian, bladder and prostate cancers,
neuroblastoma, melanoma and sarcoma.
Pre-clinical studies have demonstrated that administration of
SCIB2 as a liposomal nanoparticle results in potent immune
responses and prolonged survival. The nanoparticle technology
utilises known lipid carriers that are optimised to deliver SCIB2
DNA to immune cells. The liposomal nanoparticles protect the DNA
from degradation and facilitate efficient uptake, expression and
T-cell activation against cancer cells. The nanoparticle delivery
system provides an alternative approach to electroporation, which
has been used to deliver other ImmunoBody(R) agents to patients.
Cancer Research UK are now planning a clinical trial to investigate
the safety and efficacy of the SCIB2-nanoparticle complex in
patients with solid tumours.
Dr Cliff Holloway, Chief Executive Officer of Scancell,
commented:
"We are delighted to announce this important milestone in our
partnership with Cancer Research UK, which moves us one step closer
to entering the clinic. This new nanoparticle approach to deliver
SCIB2 is expected to achieve results that are as effective as, or
even better than, electroporation. We believe SCIB2 has the
potential to provide a much-needed treatment option for patients
suffering from a range of common solid tumours including NSCLC, the
most frequent cause of cancer death globally."
Dr Nigel Blackburn, Cancer Research UK's director of drug
development, said:
"We're pleased to see advances in this innovative vaccine, which
could bring about urgently needed improvements for some cancers.
Our collaboration with Scancell, combining extensive expertise and
experience in drug development, will help bring this treatment to
the patients that need it sooner."
*Under the terms of the Clinical Development Partnership, Cancer
Research UK will fund and sponsor a UK-based Phase 1/2 clinical
trial; the charity's Centre for Drug Development (CDD) will be
responsible for manufacturing the clinical trial supplies of SCIB2,
conducting pre-clinical testing, sponsoring and managing the
clinical trial, including the clinical trial timelines.
Following completion of the Phase 1/2 clinical trial, Scancell
will have the option to acquire the rights to the data to support
further development of SCIB2 itself. If Scancell elects not to
exercise the option, Cancer Research UK will retain the right to
take the SCIB2 programme forward in all indications.
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They have the potential to be
used as monotherapy or in combination with checkpoint inhibitors
and other agents. This platform has the potential to enhance tumour
destruction, prevent disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial in patients with
late stage metastatic melanoma has so far successfully demonstrated
survival data of more than five years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4 T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
For further details, please see the company website:
www.scancell.co.uk
About Cancer Research UK's Clinical Development Partnerships
Clinical Development Partnership is a Cancer Research UK
initiative that aims to develop promising anti-cancer agents from
companies that are not able to take them through early phase
clinical trials themselves. Under the scheme, Cancer Research UK
sponsors and funds early clinical development, while companies
retain all underlying rights to their programmes. At the end of the
study, companies can decide if they wish to develop the drug
further based on the clinical trial results. If they choose not to,
the charity may secure an alternative partner and ensure the drug
has every possible chance of reaching patients, with a share of
future income returned to Cancer Research UK.
About Cancer Research UK's Centre for Drug Development
Cancer Research UK has an impressive record of developing novel
treatments for cancer. The Cancer Research UK Centre for Drug
Development, formerly the Drug Development Office, has been
pioneering the development of new cancer treatments for more than
25 years, taking over 140 potential new anti-cancer agents into
clinical trials in patients. Six of these new agents have made it
to market including temozolomide for brain cancer, abiraterone for
prostate cancer and rucaparib for ovarian cancer, and two other
drugs are in late development Phase III trials. Cancer Research UK
currently has a portfolio of around 30 new anti-cancer agents in
preclinical development, Phase I or early Phase II clinical
trials.
About Cancer Research UK
-- Cancer Research UK is the world's leading cancer charity
dedicated to saving lives through research.
-- Cancer Research UK's pioneering work into the prevention,
diagnosis and treatment of cancer has helped save millions of
lives.
-- Cancer Research UK receives no government funding for its
life-saving research. Every step it makes towards beating cancer
relies on vital donations from the public.
-- Cancer Research UK has been at the heart of the progress that
has already seen survival in the UK double in the last 40
years.
-- Today, 2 in 4 people survive their cancer for at least 10
years. Cancer Research UK's ambition is to accelerate progress so
that by 2034, 3 in 4 people will survive their cancer for at least
10 years.
-- Cancer Research UK supports research into all aspects of
cancer through the work of over 4,000 scientists, doctors and
nurses.
-- Together with its partners and supporters, Cancer Research
UK's vision is to bring forward the day when all cancers are
cured.
For further information about Cancer Research UK's work or to
find out how to support the charity, please call 0300 123 1022 or
visit www.cancerresearchuk.org. Follow us on Twitter and
Facebook.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFMGMKVLFGLZM
(END) Dow Jones Newswires
May 20, 2019 02:01 ET (06:01 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024